David Keith
Dr. Sam Giles
Search results
Jul 30, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COV™ (casirivimab and imdevimab).
Aug 13, 2021 · REGEN-COV is a type of monoclonal antibody treatment that helps reduce the risk of developing severe COVID-19 after someone has been exposed to the virus. It binds to the spike protein in SARS-CoV-2, the virus that causes COVID-19, and keeps it from attacking your cells.
On June 27, 2022, FDA authorized an extension to the shelf-life from 24 months to 30 months for specific lots of the refrigerated Regeneron monoclonal antibodies, casirivimab and imdevimab, administered together or REGEN-COV (see Table 1, Table 2, and Table 3 below).
REGEN-COV is an investigational medicine used in adults and adolescents (12 years of age and older who weigh at least 88 pounds (40 kg)) who are at high risk for severe COVID-19, including...
Aug 4, 2021 · REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among...
About us. We are an independent not-for-profit that uses our expertise to work with industry, communities and the public sector to revolutionise the way we generate, supply and use energy. Regen...
Q. What does this EUA authorize? What are the limitations of authorized use? A. This EUA authorizes the emergency use of the investigational drug product REGEN-COV (casirivimab and imdevimab)...
